The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist
The industry’s next major competitor may never build another national laboratory network or employ thousands of phlebotomists. It may simply own the device that notices something first.
Startup Supporting Caregivers Raises $3.5M in Seed Funding
Avanlee Care's seed round was led by BEA Venture Fund, with participation from existing investors, including Board Chair Esther Dyson, Chrysalis Ventures and FairBridge VC.
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now.
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
Argenx’s Unnatural Products acquisition brings a macrocyclic peptides discovery platform for developing oral peptide drugs. The deal brings a new modality to Argenx, whose immunology R&D had focused on antibodies.
Simulation-Guided Clinical Trials: Is EU Law Ready?
Simulations do not replace human judgment: they inform it, making transparent what would otherwise remain a “black box.” EU law does not require them today; but a proportionate embrace, in the right legislative vehicle, with clear methodological standards, and without crushing noncommercial research, could make trials safer, faster, cheaper, and more reliable, without sacrificing rigor.